Home Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a...
 

Keywords :   


Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a...

2014-01-23 08:48:30| Biotech - Topix.net

Alnylam Pharmaceuticals , Inc. , a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 study with ALN - AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin for the treatment of hemophilia and rare bleeding disorders .

Tags: a trial phase clinical

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
16.11SRAM Level T
16.11 alone at home t XL
16.11S.H.Figuarts()
16.112
16.11QMSV XX Meilin 40cm
16.11LP
16.11The Study of COMME des GARCONS SWITCH
16.11
More »